Calypte(765254) scheint aufzuerstehen!
18.09.07 10:05
#105
Biomedi
Bei 102% in nur gut 4 Monaten sollte ich doch noch
weitere grüne Pumkte bekommen; denkt ihr nicht?
18.09.07 10:27
#108
LuckyStrike
ja Bio grüner Stern grins
Position- Long; ST Rating- Strong Buy; LT Rating- Strong Buy
18.09.07 13:16
#109
Biomedi
109% seit meinem Threadbeginn im Juli!
Heute gibts eine Sternregen...und Geldregen...
18.09.07 13:24
#110
gindants
gratuliere biomedi
der chart hat nach oben gedreht... good luck euch!!
18.09.07 14:05
#111
didi89129
News
Calypte's Aware(R) HIV-1/2 OMT Oral Fluid Rapid Test Approved in USAID Waiver List
Approval Opens $15 Billion PEPFAR Markets; Company To Hold Conference Call at 10:30 am Eastern time today
PORTLAND, Ore.--(BUSINESS WIRE)--
Calypte Biomedical Corporation (OTCBB: CBMC), a manufacturer of medical diagnostic tests for the rapid detection of antibodies to the human immunodeficiency virus (HIV), announced today that its Aware(R) HIV-1/2 OMT oral fluid rapid test has been approved by the U.S. Agency for International Development ("USAID"). The Aware(R) product has been placed on the USAID rapid HIV test waiver list, which under the U.S. Acquisition & Assistance Policy Directive (AAPD 05-01) permits use of the Aware(R) test in USAID-funded projects. The inclusion now permits countries such as South Africa, Kenya and Uganda, where the Company's HIV Test is approved, to purchase Aware(R) using funding from the President's Emergency Plan for AIDS Relief ("PEPFAR"), which was first announced in 2003 and subsequently reaffirmed and increased this past January when President George W. Bush asked Congress to commit $15 billion over the next five years, including nearly $10 billion in new money, to combat AIDS. PEPFAR is the largest commitment ever by any nation for an international health initiative dedicated to a single disease.
The evaluation was directed, reviewed and approved by the U.S. Centers for Disease Control and Prevention (the "CDC") which has the responsibility for evaluation of all rapid HIV tests for the USAID. The CDC determined that our test satisfied the USAID requirements and recommended its inclusion in the list of products available for purchase by countries receiving USAID funds. USAID has added the kit to its latest update of the waiver list - (http://www.usaid.gov/ our_work/global_health/aids/TechAreas/scms/scms.html). (Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.)
Roger I. Gale, Chairman and Chief Executive Officer of Calypte noted, "This represents a major breakthrough for us on two fronts. First, our oral fluid test, now eligible to be purchased by USAID, has gained access to the biggest single source of purchasing power for rapid HIV tests in the world. And, as we continue to gain additional country approvals, our market opportunities will expand even further. Second, by matching the results of the other rapid blood tests in the CDC evaluation, the results validated what we have always known. Specifically, this rapid oral fluid test is a highly accurate, efficacious test which holds its own against what are considered some of the best rapid blood tests in the world. The performance of our product, together with the safety, simplicity and ease-of-use features and USAID approval will, we believe, drive sales in countries where our test can now be acquired with PEPFAR funds. We believe this validation also adds credibility in the private sector, and in fact we have already received strong interest from potential new customers in South Africa in anticipation of this approval and expect increased sales as a direct result of this approval."
Dr. Ronald Mink, Calypte's Chief Science Officer expanded, "By meeting the stringent USAID criteria for addition to their waiver list, Aware(R) HIV-1/2 OMT again demonstrates accuracy equal to what many consider the best of the rapid blood-based rapid tests available. One component of the current study compared the results of testing oral fluid and blood collected from the same subjects at the same clinic visit. Oral fluid was tested by the Aware(R) HIV-1/2 OMT Rapid Test and blood by Determine(TM) HIV-1/2, the most widely used rapid HIV test in the world and Uni-Gold(TM) HIV, a test approved by the U.S. FDA. In this study, all subjects who tested positive by Aware(R) HIV-1/2 OMT had their blood tested by both Determine(TM) HIV-1/2 and Uni-Gold(TM) HIV. For all of these subjects, the results from all three tests were concordant. Subjects who tested negative by Aware(R) HIV-1/2 OMT had their blood tested by Determine(TM) HIV-1/2. Again, the results of Aware(R) with this blood testing were 100% concordant."
Approval Opens $15 Billion PEPFAR Markets; Company To Hold Conference Call at 10:30 am Eastern time today
PORTLAND, Ore.--(BUSINESS WIRE)--
Calypte Biomedical Corporation (OTCBB: CBMC), a manufacturer of medical diagnostic tests for the rapid detection of antibodies to the human immunodeficiency virus (HIV), announced today that its Aware(R) HIV-1/2 OMT oral fluid rapid test has been approved by the U.S. Agency for International Development ("USAID"). The Aware(R) product has been placed on the USAID rapid HIV test waiver list, which under the U.S. Acquisition & Assistance Policy Directive (AAPD 05-01) permits use of the Aware(R) test in USAID-funded projects. The inclusion now permits countries such as South Africa, Kenya and Uganda, where the Company's HIV Test is approved, to purchase Aware(R) using funding from the President's Emergency Plan for AIDS Relief ("PEPFAR"), which was first announced in 2003 and subsequently reaffirmed and increased this past January when President George W. Bush asked Congress to commit $15 billion over the next five years, including nearly $10 billion in new money, to combat AIDS. PEPFAR is the largest commitment ever by any nation for an international health initiative dedicated to a single disease.
The evaluation was directed, reviewed and approved by the U.S. Centers for Disease Control and Prevention (the "CDC") which has the responsibility for evaluation of all rapid HIV tests for the USAID. The CDC determined that our test satisfied the USAID requirements and recommended its inclusion in the list of products available for purchase by countries receiving USAID funds. USAID has added the kit to its latest update of the waiver list - (http://www.usaid.gov/ our_work/global_health/aids/TechAreas/scms/scms.html). (Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.)
Roger I. Gale, Chairman and Chief Executive Officer of Calypte noted, "This represents a major breakthrough for us on two fronts. First, our oral fluid test, now eligible to be purchased by USAID, has gained access to the biggest single source of purchasing power for rapid HIV tests in the world. And, as we continue to gain additional country approvals, our market opportunities will expand even further. Second, by matching the results of the other rapid blood tests in the CDC evaluation, the results validated what we have always known. Specifically, this rapid oral fluid test is a highly accurate, efficacious test which holds its own against what are considered some of the best rapid blood tests in the world. The performance of our product, together with the safety, simplicity and ease-of-use features and USAID approval will, we believe, drive sales in countries where our test can now be acquired with PEPFAR funds. We believe this validation also adds credibility in the private sector, and in fact we have already received strong interest from potential new customers in South Africa in anticipation of this approval and expect increased sales as a direct result of this approval."
Dr. Ronald Mink, Calypte's Chief Science Officer expanded, "By meeting the stringent USAID criteria for addition to their waiver list, Aware(R) HIV-1/2 OMT again demonstrates accuracy equal to what many consider the best of the rapid blood-based rapid tests available. One component of the current study compared the results of testing oral fluid and blood collected from the same subjects at the same clinic visit. Oral fluid was tested by the Aware(R) HIV-1/2 OMT Rapid Test and blood by Determine(TM) HIV-1/2, the most widely used rapid HIV test in the world and Uni-Gold(TM) HIV, a test approved by the U.S. FDA. In this study, all subjects who tested positive by Aware(R) HIV-1/2 OMT had their blood tested by both Determine(TM) HIV-1/2 and Uni-Gold(TM) HIV. For all of these subjects, the results from all three tests were concordant. Subjects who tested negative by Aware(R) HIV-1/2 OMT had their blood tested by Determine(TM) HIV-1/2. Again, the results of Aware(R) with this blood testing were 100% concordant."
18.09.07 14:09
#112
didi89129
Ergänzung
About USAID:
USAID (www.usaid.gov) is the U.S. government agency responsible for worldwide humanitarian and development assistance. USAID provides assistance in four regions of the world: Sub-Saharan Africa; Asia and the Near East; Latin America and the Caribbean and Europe and Eurasia. Since the inception of its HIV/AIDS program in 1986, the USAID has funded over $6 billion in the fight against this pandemic - more than any other public or private organization - to significantly expand quality HIV/AIDS prevention, care and treatment interventions. USAID currently has HIV/AIDS programs in nearly 100 countries worldwide.
USAID (www.usaid.gov) is the U.S. government agency responsible for worldwide humanitarian and development assistance. USAID provides assistance in four regions of the world: Sub-Saharan Africa; Asia and the Near East; Latin America and the Caribbean and Europe and Eurasia. Since the inception of its HIV/AIDS program in 1986, the USAID has funded over $6 billion in the fight against this pandemic - more than any other public or private organization - to significantly expand quality HIV/AIDS prevention, care and treatment interventions. USAID currently has HIV/AIDS programs in nearly 100 countries worldwide.
18.09.07 16:29
#114
LarsvomMars
Pffffffffffffffffffffffffft - die heiße Luft
entweicht mal wieder. Was für ein weltbewegendes Statement!
Ministerium für außerplanetarische Angelegenheiten/
Außenkolonienkontaktdienst
Ministerium für außerplanetarische Angelegenheiten/
Außenkolonienkontaktdienst
18.09.07 18:53
#115
didi89129
Wie werten wir die News und conference call?
Sicher ist es richtig, dass die Umsätze noch spärlich sind ... aber was viel wichtiger ist, dass Calypte nun in einem national aufgelegten Programm mit weltweiter Wirkung aktiv eingebunden ist, das insgesamt ein Milliardenvolumen darstellt. Davon kann Caly durch den anerkannten und sicheren Test seine Umsätze in einem früheren Stadium machen als die anderen Partner, denn eine Behandlung erfolgt erst nach der Diagnose.
Ich bin weiter sehr optimistisch für Caly! Gale sprach auch schon von weiteren Auftragseingängen. Die Verteilung scheint noch das Problem zu sein. Habe es nicht ganz gerafft.
Weitere Meinungen?
Didi
Ich bin weiter sehr optimistisch für Caly! Gale sprach auch schon von weiteren Auftragseingängen. Die Verteilung scheint noch das Problem zu sein. Habe es nicht ganz gerafft.
Weitere Meinungen?
Didi
18.09.07 21:19
#116
OttomanRosendah.
@LarsvomMars
alias Udo ; = )
heiße Luft ??
Wir haben enorme große Erwartungen gehabt und die sind vorerst nicht eingetroffen,was nicht heißt, das sie nicht eintreffen werden...
alias Udo ; = )
heiße Luft ??
Wir haben enorme große Erwartungen gehabt und die sind vorerst nicht eingetroffen,was nicht heißt, das sie nicht eintreffen werden...
18.09.07 21:29
#117
LarsvomMars
So wie immer halt
Ministerium für außerplanetarische Angelegenheiten/
Außenkolonienkontaktdienst
Ministerium für außerplanetarische Angelegenheiten/
Außenkolonienkontaktdienst
19.09.07 10:58
#118
didi89129
So, auf ein Neues
die erste Enttäuschung ist überwunden.
Leider wurden (noch) keine großen Verkaufszahlen gemeldet, aber ....
die Meldung mit der Aufnahme in PEPFAR bietet dennoch gewaltige Chancen. Das ist unbestritten. Erfordert noch Geduld. Der Blick auf das Potenzial ist dennoch mehr als ermutigend.
Didi
Leider wurden (noch) keine großen Verkaufszahlen gemeldet, aber ....
die Meldung mit der Aufnahme in PEPFAR bietet dennoch gewaltige Chancen. Das ist unbestritten. Erfordert noch Geduld. Der Blick auf das Potenzial ist dennoch mehr als ermutigend.
Didi
26.09.07 11:56
#120
Biomedi
Heute und morgen wichtige Termine!
In Berlin wird heute und morgen ueber die Zusagen der vers. Laender in einer Groessenordnung von 60 Mrd. Dollar zur Bekaempfung von Aids/HIV , Malaria und Tuberkulose beim Treffen in Heiligendamm bzw. im Zusammenhang mit dem World Aids Konzert im Sommer gesprochen und wohl Vorentscheidungen getroffen.
27.09.07 12:57
#123
ConnyM
dollarschwäche
na da wird wohl schon das risiko einer weiteren dollarschwäche mit eingerechnet.....:)